Godavari Drugs Limited has fixed the book closure period from September 19, 2026 to September 25, 2026 for its 38th Annual General Meeting. The meeting is scheduled to take place on September 25, 2026 at 3:00 pm via Video Conferencing or Other Audio Visual Means.

The company previously announced that its board approved an alteration to its Memorandum of Association to enter the nutraceuticals and dietary supplements business. This amendment requires shareholder approval at the upcoming AGM.

Book Closure and Voting Details

The Register of Members and Share Transfer Books will remain closed from Saturday, September 19, 2026 to Friday, September 25, 2026 (both days inclusive). This closure determines the members entitled to vote at the meeting.

Shareholders holding shares in physical or dematerialized form can cast their votes electronically during the e-voting window. The cut-off date for ascertaining eligible shareholders is September 18, 2026.

Strategic Rationale

The existing main objects clause covers drugs and pharmaceuticals but does not explicitly authorize the proposed line of business. The new segment is governed under the Food Safety and Standards Act, 2006. The alteration enables the company to validly carry out domestic and export marketing, third-party contract manufacturing, and own manufacturing of bulk ingredients and formulations in this sector.

Shareholder Approval Process

The amendment requires approval by way of a Special Resolution under Section 13 of the Companies Act, 2013. The resolution will be placed before members at the 38th Annual General Meeting.

The alteration is additive in nature and does not involve discontinuing any existing business activities. It does not affect the existing rights of members or the nature of their liability. The amendment will take effect upon member approval and filing of Form MGT-14 with the Registrar of Companies, Telangana.

Godavari Drugs reported no deviation or variation in the utilisation of funds raised through its preferential issue for the quarter ended June 30, 2026. The company raised a total of ₹4,411.73 lakh on March 18, 2026, and confirmed that the funds were deployed strictly according to the originally disclosed objects.

The Board of Directors considered and approved the Statement on Deviation or Variation in Utilisation of Funds at its meeting held on August 14, 2026. The filing was submitted to the BSE Limited pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Fund Utilisation Breakdown

The preferential issue proceeds were allocated across three primary objects: capital expenditure, working capital requirements, and repayment of unsecured loans to promoters and directors. During the quarter, the company utilised funds only for capital expenditure purposes.

The capital expenditure was directed towards manufacturing Active Pharmaceutical Ingredients (APIs), intermediates, and specialty chemicals in therapeutic categories including Anti-HIV and CNS segments. Specific utilisations included civil construction for production blocks, procurement and installation of equipment such as reactors and heat exchangers, and augmentation of electrical infrastructure.

Compliance and Oversight

The Audit Committee reviewed the statement and recorded no comments, indicating compliance with the approved fund utilisation plan. Similarly, the auditors provided no comments on the deviation report. No monitoring agency was appointed for this issue.

There were no modifications to the original objects of the fund raising, nor any changes in the terms of the contract as disclosed in the fund raising documents. Consequently, no shareholder approval was required for variations during this quarter.